Cancer-Specific Mortality Versus Overall Survival in Prostate Cancer Screening

Why It Matters

The critique highlights that policy and clinical decisions based on flawed endpoints could misguide resource allocation and patient care, underscoring the need for robust OS data in prostate cancer screening.

Key Takeaways

• Cancer-specific mortality prone to cause-of-death misclassification.
• No randomized trial shows overall survival benefit from PSA screening.
• Estimated two lives saved per 1,000 screened is highly uncertain.
• Overdiagnosis requires evidence of unchanged overall survival in screened groups.
• Future trials must prioritize overall survival as primary endpoint.

Pulse Analysis

Prostate cancer screening has long been justified by modest reductions in cancer‑specific mortality, yet the metric’s susceptibility to classification bias raises doubts about its clinical relevance. Overall survival (OS) remains the gold standard for measuring treatment impact because it captures all-cause mortality without relying on subjective cause-of-death attribution. Recent analyses, including the BMJ correspondence by Takahashi, emphasize that no large‑scale randomized trial has yet proven that PSA‑based screening translates into a measurable OS advantage, casting a shadow over the purported benefit of saving two lives per 1,000 screened men.

The methodological flaws inherent in cancer‑specific mortality become especially pronounced when evaluating overdiagnosis and overtreatment. Overdiagnosis should be demonstrated only when screen‑detected cancers do not affect OS compared with an unscreened cohort, while overtreatment requires proof that therapeutic intervention improves OS beyond what would occur without treatment. Current evidence fails to meet these criteria, leaving the true magnitude of benefit ambiguous and the cost‑effectiveness of mass screening questionable. Moreover, reliance on uncertain endpoints destabilizes benefit‑risk assessments, potentially inflating perceived advantages while underestimating harms such as unnecessary biopsies, anxiety, and treatment complications.

For policymakers, clinicians, and researchers, the imperative is clear: future prostate cancer screening trials must embed OS as a primary endpoint and ensure transparent patient consent about the limited evidence base. Ethical oversight bodies should apply CONSORT, PRISMA, and Helsinki standards rigorously, demanding robust designs that can withstand scrutiny. By shifting focus to OS, the medical community can better gauge the real value of screening programs, align resource allocation with genuine health outcomes, and restore public confidence in cancer prevention strategies.